Role of local 11β-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas

Tomoatsu Mune, Hiroyuki Morita, Takashi Suzuki, Yoshihito Takahashi, Yukinori Isomura, Tetsuya Tanahashi, Hisashi Daido, Noriyoshi Yamakita, Takashi Deguchi, Hironobu Sasano, Perrin C. White, Keigo Yasuda

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

It is not understood why some adrenal adenomas are non-functional and others with similar histopathology cause preclinical or overt Cushing's syndrome. Two isozymes of 11β-hydroxysteroid dehydrogenase, types 1 and 2 (HSD11B1 and HSD11B2), are known to modulate glucocorticoid levels in other tissues and might influence circulating levels of active and inactive glucocorticoids if they were expressed in adrenal adenomas. We determined levels of expression of these isozymes in normal adrenals and 61 adrenal adenomas by quantitative competitive RT-PCR and immunohistochemistry. There were no differences in HSD11B1 mRNA levels among adrenal tumor groups. HSD11B2 mRNA levels were high in nonfunctioning adenomas and preclinical Cushing's adenomas compared with levels in control adrenals or in adenomas causing overt Cushing's syndrome. HSD11B2 immunoreactivity was not detected in control adrenals, but was observed in more than half of these tumors. When nonfunctioning adenomas and those causing preclinical and overt Cushing's syndrome were considered as a single group, HSD11B2 mRNA levels were strongly correlated with the ratio of plasma cortisone to cortisol, and a simple model incorporating adrenal HSD11B2 expression and tumor size as variables could predict more than 50% of the interindividual variation in plasma cortisol levels (r2 = 0.54; P < 0.0001). Adrenal HSD11B2 may regulate levels of active and inactive glucocorticoids in the systemic circulation under these conditions, presumably by acting in an autocrine or paracrine manner. Nonfunctioning adenomas and those causing preclinical and overt Cushing's syndrome may represent a continuum with clinical manifestations depending mainly on tumor size and HSD11B2 expression levels.

Original languageEnglish (US)
Pages (from-to)864-870
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume88
Issue number2
DOIs
StatePublished - Feb 1 2003

Fingerprint

11-beta-Hydroxysteroid Dehydrogenases
Adenoma
Tumors
Glucocorticoids
Phenotype
Cushing Syndrome
Messenger RNA
Isoenzymes
Hydrocortisone
Plasmas
Cortisone
Tissue
Neoplasms
Glandular and Epithelial Neoplasms
Immunohistochemistry
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Role of local 11β-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas. / Mune, Tomoatsu; Morita, Hiroyuki; Suzuki, Takashi; Takahashi, Yoshihito; Isomura, Yukinori; Tanahashi, Tetsuya; Daido, Hisashi; Yamakita, Noriyoshi; Deguchi, Takashi; Sasano, Hironobu; White, Perrin C.; Yasuda, Keigo.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 88, No. 2, 01.02.2003, p. 864-870.

Research output: Contribution to journalArticle

Mune, T, Morita, H, Suzuki, T, Takahashi, Y, Isomura, Y, Tanahashi, T, Daido, H, Yamakita, N, Deguchi, T, Sasano, H, White, PC & Yasuda, K 2003, 'Role of local 11β-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas', Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 2, pp. 864-870. https://doi.org/10.1210/jc.2001-011335
Mune, Tomoatsu ; Morita, Hiroyuki ; Suzuki, Takashi ; Takahashi, Yoshihito ; Isomura, Yukinori ; Tanahashi, Tetsuya ; Daido, Hisashi ; Yamakita, Noriyoshi ; Deguchi, Takashi ; Sasano, Hironobu ; White, Perrin C. ; Yasuda, Keigo. / Role of local 11β-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas. In: Journal of Clinical Endocrinology and Metabolism. 2003 ; Vol. 88, No. 2. pp. 864-870.
@article{c5f56f3c856d446fb94c633e07dcd881,
title = "Role of local 11β-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas",
abstract = "It is not understood why some adrenal adenomas are non-functional and others with similar histopathology cause preclinical or overt Cushing's syndrome. Two isozymes of 11β-hydroxysteroid dehydrogenase, types 1 and 2 (HSD11B1 and HSD11B2), are known to modulate glucocorticoid levels in other tissues and might influence circulating levels of active and inactive glucocorticoids if they were expressed in adrenal adenomas. We determined levels of expression of these isozymes in normal adrenals and 61 adrenal adenomas by quantitative competitive RT-PCR and immunohistochemistry. There were no differences in HSD11B1 mRNA levels among adrenal tumor groups. HSD11B2 mRNA levels were high in nonfunctioning adenomas and preclinical Cushing's adenomas compared with levels in control adrenals or in adenomas causing overt Cushing's syndrome. HSD11B2 immunoreactivity was not detected in control adrenals, but was observed in more than half of these tumors. When nonfunctioning adenomas and those causing preclinical and overt Cushing's syndrome were considered as a single group, HSD11B2 mRNA levels were strongly correlated with the ratio of plasma cortisone to cortisol, and a simple model incorporating adrenal HSD11B2 expression and tumor size as variables could predict more than 50{\%} of the interindividual variation in plasma cortisol levels (r2 = 0.54; P < 0.0001). Adrenal HSD11B2 may regulate levels of active and inactive glucocorticoids in the systemic circulation under these conditions, presumably by acting in an autocrine or paracrine manner. Nonfunctioning adenomas and those causing preclinical and overt Cushing's syndrome may represent a continuum with clinical manifestations depending mainly on tumor size and HSD11B2 expression levels.",
author = "Tomoatsu Mune and Hiroyuki Morita and Takashi Suzuki and Yoshihito Takahashi and Yukinori Isomura and Tetsuya Tanahashi and Hisashi Daido and Noriyoshi Yamakita and Takashi Deguchi and Hironobu Sasano and White, {Perrin C.} and Keigo Yasuda",
year = "2003",
month = "2",
day = "1",
doi = "10.1210/jc.2001-011335",
language = "English (US)",
volume = "88",
pages = "864--870",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Role of local 11β-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas

AU - Mune, Tomoatsu

AU - Morita, Hiroyuki

AU - Suzuki, Takashi

AU - Takahashi, Yoshihito

AU - Isomura, Yukinori

AU - Tanahashi, Tetsuya

AU - Daido, Hisashi

AU - Yamakita, Noriyoshi

AU - Deguchi, Takashi

AU - Sasano, Hironobu

AU - White, Perrin C.

AU - Yasuda, Keigo

PY - 2003/2/1

Y1 - 2003/2/1

N2 - It is not understood why some adrenal adenomas are non-functional and others with similar histopathology cause preclinical or overt Cushing's syndrome. Two isozymes of 11β-hydroxysteroid dehydrogenase, types 1 and 2 (HSD11B1 and HSD11B2), are known to modulate glucocorticoid levels in other tissues and might influence circulating levels of active and inactive glucocorticoids if they were expressed in adrenal adenomas. We determined levels of expression of these isozymes in normal adrenals and 61 adrenal adenomas by quantitative competitive RT-PCR and immunohistochemistry. There were no differences in HSD11B1 mRNA levels among adrenal tumor groups. HSD11B2 mRNA levels were high in nonfunctioning adenomas and preclinical Cushing's adenomas compared with levels in control adrenals or in adenomas causing overt Cushing's syndrome. HSD11B2 immunoreactivity was not detected in control adrenals, but was observed in more than half of these tumors. When nonfunctioning adenomas and those causing preclinical and overt Cushing's syndrome were considered as a single group, HSD11B2 mRNA levels were strongly correlated with the ratio of plasma cortisone to cortisol, and a simple model incorporating adrenal HSD11B2 expression and tumor size as variables could predict more than 50% of the interindividual variation in plasma cortisol levels (r2 = 0.54; P < 0.0001). Adrenal HSD11B2 may regulate levels of active and inactive glucocorticoids in the systemic circulation under these conditions, presumably by acting in an autocrine or paracrine manner. Nonfunctioning adenomas and those causing preclinical and overt Cushing's syndrome may represent a continuum with clinical manifestations depending mainly on tumor size and HSD11B2 expression levels.

AB - It is not understood why some adrenal adenomas are non-functional and others with similar histopathology cause preclinical or overt Cushing's syndrome. Two isozymes of 11β-hydroxysteroid dehydrogenase, types 1 and 2 (HSD11B1 and HSD11B2), are known to modulate glucocorticoid levels in other tissues and might influence circulating levels of active and inactive glucocorticoids if they were expressed in adrenal adenomas. We determined levels of expression of these isozymes in normal adrenals and 61 adrenal adenomas by quantitative competitive RT-PCR and immunohistochemistry. There were no differences in HSD11B1 mRNA levels among adrenal tumor groups. HSD11B2 mRNA levels were high in nonfunctioning adenomas and preclinical Cushing's adenomas compared with levels in control adrenals or in adenomas causing overt Cushing's syndrome. HSD11B2 immunoreactivity was not detected in control adrenals, but was observed in more than half of these tumors. When nonfunctioning adenomas and those causing preclinical and overt Cushing's syndrome were considered as a single group, HSD11B2 mRNA levels were strongly correlated with the ratio of plasma cortisone to cortisol, and a simple model incorporating adrenal HSD11B2 expression and tumor size as variables could predict more than 50% of the interindividual variation in plasma cortisol levels (r2 = 0.54; P < 0.0001). Adrenal HSD11B2 may regulate levels of active and inactive glucocorticoids in the systemic circulation under these conditions, presumably by acting in an autocrine or paracrine manner. Nonfunctioning adenomas and those causing preclinical and overt Cushing's syndrome may represent a continuum with clinical manifestations depending mainly on tumor size and HSD11B2 expression levels.

UR - http://www.scopus.com/inward/record.url?scp=0037326184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037326184&partnerID=8YFLogxK

U2 - 10.1210/jc.2001-011335

DO - 10.1210/jc.2001-011335

M3 - Article

C2 - 12574226

AN - SCOPUS:0037326184

VL - 88

SP - 864

EP - 870

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -